portfolio detail AlloMek Therapeutics

Venture Portfolio

AlloMek Therapeutics

About:
AlloMek Therapeutics was formed to develop, and out-license, a novel class of MEK inhibitors represented by the lead compound CIP-137401.

Website:
www.allomek.optimatrix.net

CI Representative:
Daniel Wagner
Managing Director, Investments

back to portfolio